ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 698

Is It Possible to Identify Psoriasis Patients Who Will Develop Axial Disease? Real Life Data from Psart (Psoriatic Arthritis Registry of Turkey)

Sibel Z. Aydin1, Ozun Bayndır1, Barış Yılmazer1, Kenan Aksu1, Ediz Dalkilic2, Mustafa Ferhat Oksuz1, E.Figen Tarhan1, Meryem Can1, Orhan Kucuksahin1, Gezmis Kimyon1, Lutfi Akyol1, Ahmet Mesut Onat1, Bunyamin Kisacik1, Abdulsamet Erden1, Ahmet Omma1, Duygu Ersozlu Bakirli1, Cem Ozisler1, Emel Gonullu1, Seval Pehlevan1, Dilek Solmaz1, Muhammet Cinar1, Gozde Cetin1, Abdurrahman Tufan1, Muge Aydin Tufan1, Levent Kilic1, Sukran Erten1, Timucin Kasifoglu1, Senol Kobak1, Soner Senel1, Servet Akar1, Metin Ozgen1, Esen Kasapoglu-Gunal1, Veli Yazisiz1, Sedat Yılmaz1, Salim Donmez1, İsmail Dogan1, Hamide Kart Koseoglu1, Funda Erbasan1, Fatih Yildiz1, Cemal Bes1, Ayse Balkarli1, Ali Sahin1, Rıdvan Mercan1, Fatoş Arslan1, Atalay Dogru1, Salih Pay1, Sule Yavuz1, Necati Cakir1, Yasemin Kabasakal1 and Umut Kalyoncu1, 1PsART study group, Ankara, Turkey, 2Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Axial spondyloarthritis and psoriasis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Is
it possible to identify psoriasis patients who will develop axial disease? Real life data from PsART
(Psoriatic Arthritis Registry of Turkey)

S. Z. Aydýn, Ö. Bayýndýr 1  , B.
Yýlmazer 1,K. Aksu 1, E. Dalkýlýç 1, M. F.
Öksüz 1, E. F. Tarhan 1, M. Can 1, O.
Küçükþahin 1 , G. Kimyon 1, L. Akyol 1, A. M.
Onat 1, B. Kýsacýk 1, A. Erden 1, A. Omma 1,
E. D. Ersözlü Bozkýrlý 1, C. Öziþler 1, E. Gönüllü 1
, S. Masatlýoglu Pehlevan 1, D. Solmaz 1, M. Çýnar 1,
G. Yýldýrým Çetin 1, A. Tufan 1, M. Aydýn Tufan 1,
L. Kýlýç 1, S. Erten 1, T. Kaþifoglu 1, S.
Kobak 1, S. Þenel 1, S. Akar 1, M. Özgen 1,
E. Kasapoglu Günal 1, V. Yazýsýz 1, S. Yýlmaz 1,
S. Dönmez 1, I. Dogan 1, H. Kart Köseoglu 1,
F. Erbasan 1, F. Yýldýz 1, C. Bes 1, A.
Balkarlý 1, A. Þahin 1, R. Mercan 1, F. Arslan
1, A. Dogru 1, S. Pay 1, S. Yavuz 1,
N. Çakýr 1, Y. Kabasakal 1, U. Kalyoncu

1PsART
study group, Ankara, Turkey

Background/Purpose:Psoriatic arthritis (PsA) is a complex disease with various patterns
of joint involvement. PsART (Psoriatic Arthritis
Registry of Turkey) is a prospective,
multicentre, nationwide study in Turkey which was built with the objective of understanding the nature of the disease, clarify differences
among different presentation types of PsA and identifying poor prognostic factors.
Here we present the cross sectional characteristics of
a large group of PsA patients from the registry, with an emphasis on factors
associated with axial disease.

Methods: PsART was built in May 2014. Patients are consecutively recruited to
this registry, if they are diagnosed as PsA, regardless of any disease
characteristics. Data collection was performed through a website. Disease
characteristics, treatments and comorbidities were collected in addition to
disease activity and function assessment.

Results: Until June 2015, 1060 patients were recruited. Within these 64.5 % (684/1060)
were female.. The mean (SD) duration of PsA was 77.7 (89) months. Arthritis was
the initial finding in 4.4% and psoriasis preceded in 85.8% (Table).  Patients
with axial involvement were significantly younger than the other forms of
arthritis (p<0.0001). Other factors that were associated with axial disease
were type of psoriasis (pustular type 31.4% in axial disease vs 21.4 in
non-axial forms; p=0.008), smoking (43.7% vs 33.3%; p=0.008) and having nail
disease (53.3% vs 44.6%; 0.013).

Patients who had
pustular type of psoriasis, nail disease and smoked had a 1.86 relative risk
for having axial disease compared to patients who doesn’t have at least one
them.

Conclusion: The patient characteristics of the PsART are comparable to the
previously reported registries, supporting its external validity.  The pattern
of arthritis may be foreseen in patients with pustular type of psoriasis and
nail disease especially if they have a history of smoking.

 

Age (mean(SD))

47 (12.9)

BMI (mean (SD))

28 (5.2)

Polyarthritis n (%)

373 (35.2%)

Axial involvement n (%)

270 (25.9%)

Oligoarthritis n (%)

296 (28.4%)

Monoarthritis (%)

30 (2.8%)

DIP joint involvement n (%)

67 (6.3%)

Arthritis mutilans n (%)

6 (0.6%)

Nail disease

504 (47.5%)

Table: Characteristics of PsA patients from
PsART. *: data given as mean (SD).


Disclosure: S. Z. Aydin, None; O. Bayndır, None; B. Yılmazer, None; K. Aksu, None; E. Dalkilic, None; M. F. Oksuz, None; E. F. Tarhan, None; M. Can, None; O. Kucuksahin, None; G. Kimyon, None; L. Akyol, None; A. M. Onat, None; B. Kisacik, None; A. Erden, None; A. Omma, None; D. Ersozlu Bakirli, None; C. Ozisler, None; E. Gonullu, None; S. Pehlevan, None; D. Solmaz, None; M. Cinar, None; G. Cetin, None; A. Tufan, None; M. Aydin Tufan, None; L. Kilic, None; S. Erten, None; T. Kasifoglu, None; S. Kobak, None; S. Senel, None; S. Akar, None; M. Ozgen, None; E. Kasapoglu-Gunal, None; V. Yazisiz, None; S. Yılmaz, None; S. Donmez, None; Dogan, None; H. Kart Koseoglu, None; F. Erbasan, None; F. Yildiz, None; C. Bes, None; A. Balkarli, None; A. Sahin, None; R. Mercan, None; F. Arslan, None; A. Dogru, None; S. Pay, None; S. Yavuz, None; N. Cakir, None; Y. Kabasakal, None; U. Kalyoncu, None.

To cite this abstract in AMA style:

Aydin SZ, Bayndır O, Yılmazer B, Aksu K, Dalkilic E, Oksuz MF, Tarhan EF, Can M, Kucuksahin O, Kimyon G, Akyol L, Onat AM, Kisacik B, Erden A, Omma A, Ersozlu Bakirli D, Ozisler C, Gonullu E, Pehlevan S, Solmaz D, Cinar M, Cetin G, Tufan A, Aydin Tufan M, Kilic L, Erten S, Kasifoglu T, Kobak S, Senel S, Akar S, Ozgen M, Kasapoglu-Gunal E, Yazisiz V, Yılmaz S, Donmez S, Dogan , Kart Koseoglu H, Erbasan F, Yildiz F, Bes C, Balkarli A, Sahin A, Mercan R, Arslan F, Dogru A, Pay S, Yavuz S, Cakir N, Kabasakal Y, Kalyoncu U. Is It Possible to Identify Psoriasis Patients Who Will Develop Axial Disease? Real Life Data from Psart (Psoriatic Arthritis Registry of Turkey) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/is-it-possible-to-identify-psoriasis-patients-who-will-develop-axial-disease-real-life-data-from-psart-psoriatic-arthritis-registry-of-turkey/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-it-possible-to-identify-psoriasis-patients-who-will-develop-axial-disease-real-life-data-from-psart-psoriatic-arthritis-registry-of-turkey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology